Gene Therapy 13Fs: CRISPR, Intellia, Beam, Editas, Sarepta

US gene therapy equities form a distinctive innovation-driven specialty-biotech corner of institutional 13F positioning. CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and Sarepta Therapeutics (SRPT) anchor the cohort. Multi-year clinical milestone cycles, manufacturing scaling challenges, reimbursement framework development, and ongoing M&A activity drive distinctive institutional patterns. Reading gene therapy 13F positioning requires understanding the clinical-milestone framework plus the multi-year manufacturing and reimbursement cycle dynamics.

The gene therapy business model

Gene therapy faces four primary economic drivers:

1. Clinical milestone cycles. Multi-year clinical trial timelines plus FDA approval pathways drive long-cycle franchise economics. Multi-year Phase 1/2 plus pivotal Phase 3 readouts produce dramatic equity revaluation.
2. Manufacturing scaling. Gene therapy manufacturing complexity (viral vectors, autologous cell therapy, plus emerging in vivo delivery) drives capacity scaling plus emerging emerging cost reduction challenges.
3. Reimbursement framework. Multi-year reimbursement framework development for one-time gene therapy treatments (multi-million dollar pricing) plus emerging outcomes-based pricing affects commercial economics.
4. M&A activity. Multi-year big pharma M&A activity (Vertex-CRISPR partnership for CASGEVY, Pfizer's Sangamo plus Beam partnerships, plus emerging acquisitions) drives valuation dynamics.

Major US gene therapy names

CRISPR Therapeutics (CRSP)

Joint developer with Vertex Pharmaceuticals of CASGEVY (first FDA-approved CRISPR therapy for sickle cell plus beta thalassemia). Multi-year pipeline expansion plus emerging in vivo plus immuno-oncology applications.

Intellia Therapeutics (NTLA)

In vivo CRISPR therapy leader with NTLA-2002 (hereditary angioedema) plus NTLA-2001 (transthyretin amyloidosis, in partnership with Regeneron). Multi-year clinical pipeline.

Beam Therapeutics (BEAM)

Base editing technology leader with BEAM-101 (sickle cell), BEAM-201 (acute lymphoblastic leukemia), plus emerging pipeline. Multi-year operational scaling.

Editas Medicine (EDIT)

CRISPR/Cas9 plus Cas12a gene editing focus. Multi-year operational restructuring plus emerging in vivo applications.

Sarepta Therapeutics (SRPT)

Duchenne muscular dystrophy (DMD) franchise (Elevidys gene therapy, plus exon-skipping antisense therapies) plus emerging limb-girdle muscular dystrophy pipeline.

How institutional managers position around gene therapy

Three patterns:

Pattern 1: CASGEVY-validation concentration

CRSP-concentrated growth manager positions reflect CASGEVY FDA approval plus expanding pipeline thesis.

Pattern 2: In-vivo CRISPR positioning

NTLA-concentrated growth manager positions reflect in vivo CRISPR therapy thesis.

Pattern 3: Commercial-franchise positioning

SRPT-concentrated active manager positions reflect Elevidys plus DMD franchise commercial thesis.

How to read gene therapy 13F positioning

Three rules:

Rule 1: Identify technology platform

CRISPR/Cas9 vs base editing vs prime editing vs viral vector have distinct economics.

Rule 2: Watch clinical milestones

Phase 3 readouts plus FDA approvals drive operator equity revaluation.

Rule 3: Cross-check M&A activity

Big pharma M&A drives valuation step changes.

What gene therapy positioning signals

1. CASGEVY-validation conviction. Concentrated CRSP positions signal CASGEVY plus pipeline thesis.
2. In-vivo CRISPR conviction. Concentrated NTLA positions signal in vivo CRISPR thesis.
3. Commercial-franchise conviction. Concentrated SRPT positions signal Elevidys franchise thesis.

For real-time tracking of gene therapy 13F activity, see the institutional signals feed.